HR BCP-ALL was defined as any ALL in patients over 18 years-old with one of the following characteristics: age>35 years, WBC count>30x109/L, pro-B phenotype, t(4;11)/KTMA or MLL rearrangements or complex karyotype….Patients in CR after the first induction cycle and MRD <0.1% entered into the trial and received 6 consolidation cycles:... 3 and 6 included blinatumomab (28 μg/day CIV infusion over 4 weeks)....The main objective of the trial was the analysis of the reduction of the MRD levels after cycles 3 and 6..... Median MRD level at inclusion was 0.03% (range: <0.0002%>0.09%), at the end of cycle 3 was 0.001% (range: 0.0002%>0.001%) and at the end of cycle 6 was <0.0002% (range: <0.0002%>0.003%). With a median follow-up of 18 months (range: 5-23) only one patient has relapsed and all patients are alive.